About
STENTiT is a Dutch MedTech company based in Eindhoven, specializing in regenerative endovascular implants. Founded in 2017 as a spin-off from Eindhoven University of Technology, the company focuses on its flagship product, the Resorbable Fibrillated Scaffold (RFS). This innovative stent promotes natural artery regeneration, offering a potential improvement over traditional stents that provide only mechanical support. The RFS is designed to treat below-the-knee chronic limb threatening ischemia (CLTI), a serious condition affecting millions of patients. STENTiT aims to enhance limb salvage rates and reduce healthcare costs with its regenerative approach. The company is also exploring applications for other vascular conditions, including aneurysms and coronary issues, and is actively pursuing clinical trials to validate its technology. STENTiT targets healthcare providers, including vascular surgeons and interventional radiologists, and has garnered support from industry leaders and venture funds. With €1.8 million in seed funding, the company is advancing its development and plans to raise additional capital for clinical trials and market expansion.
Technologies
Keywords
Company Information
- Employees16
- Founded2017
- Total Funding$1943118
Location
Eindhoven, North Brabant, Netherlands, 5611 CB
